. Against Acinetobacter baumannii the highest rates of susceptibility were for minocycline (84.5%, 14,178/16,778) and imipenem (80.0%, 3,037/3,795). The MIC 90 for tigecycline was 2 mg/L. 40% (6,743/16,778) of A. baumannii isolates were multidrug-resistant. Enterococci were highly susceptible to tigecycline and linezolid (>99%); vancomycin resistance was observed among 2% of Enterococcus faecalis (325/14,615) and 35% of Enterococcus faecium (2,136/6,167) globally. 40% (14,647/36,448) of Staphylococcus aureus were methicillin-resistant while 15% (2,152/14,562) of Streptococcus pneumoniae were penicillin-resistant. Against S. aureus and S. pneumoniae susceptibility to linezolid, vancomycin, and tigecycline was ≥99.9%. Globally, 81% (331/410) of statistically significant susceptibility changes during the study period were decreases in susceptibility. Conclusions: Amikacin, the carbapenems, and tigecycline were active against most gram-negative pathogens while linezolid, tigecycline, and vancomycin retained activity against most gram-positive pathogens collected in TEST during
Introduction
While the initial development of antimicrobial resistance mechanisms may be a local event, antimicrobial resistance has become a problem of global concern, usually resulting in prolonged and expensive therapy [1] . Global travel and migration as well as international trade have blurred the traditional geographical boundaries between countries and continents, enabling the rapid and global spread of resistant organisms [2] . Numerous important resistance mechanisms have shown alarming increases in distribution in recent years, such as extended-spectrum β-lactamases (ESBLs) and carbapenemases [3, 4] . This situation is further complicated by the current shortage of new antimicrobial development, increasing the probability that today's resistant organisms may become tomorrow's pan-resistant pathogens [5] .
The Tigecycline Evaluation and Surveillance Trial (TEST) is a global surveillance study which has been ongoing since 2004 . It has been designed specifically to monitor the in vitro activity of the broad-spectrum antimicrobial tigecycline plus comparator antimicrobial agents against numerous clinically important gram-negative and gram-positive organisms. In this report, we examine the in vitro activity of tigecycline and comparators against a collection of gram-negative and -positive organisms collected from medical centres globally between 2004 and 2013. This report updates that of Garrison et al. [6] , who examined global antimicrobial susceptibility and resistance rates between 2004 and 2007.
Materials and methods
Materials and methods for the TEST study have been published previously e.g. [7] with minimum inhibitory concentrations (MICs) determined according to the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI) [8] .
After receipt by the central laboratory, International Health Management Associates, Inc. (IHMA, Schaumberg, IL, USA), organism identification confirmation was carried out on all isolates using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (Bruker Daltronics, Bremen, Germany).
Antimicrobial susceptibility was determined using breakpoints approved by the CLSI [9] with the (US) Food and Drug Administration (FDA) breakpoints used for tigecycline [10] . FDA tigecycline breakpoints for Enterococcus faecalis (vancomycin-susceptible) were used for all Enterococcus isolates in this study and penicillin oral breakpoints (susceptible ≤0.06 mg/L, resistant ≥2 mg/L) were used for Streptococcus pneumoniae.
Multidrug resistance
For the purposes of this manuscript, multidrug-resistant (MDR) was defined as resistance to three or more classes of antimicrobial agents. The classes used to define MDR among the Enterobacteriaceae were aminoglycosides (amikacin), β-lactams (ampicillin, amoxicillin/clavulanate, cefepime, ceftriaxone, or piperacillin-tazobactam), carbapenems (imipenem/meropenem), fluoroquinolones (levofloxacin), glycylcyclines (tigecycline), and tetracyclines (minocycline); the classes used to define MDR A. baumannii were aminoglycosides (amikacin), β-lactams (cefepime, ceftazidime, ceftriaxone, or piperacillintazobactam), carbapenems (imipenem/meropenem), fluoroquinolones (levofloxacin), and tetracyclines (minocycline); and the classes used to define MDR P. aeruginosa were aminoglycosides (amikacin), β-lactams (cefepime, ceftazidime, or piperacillin-tazobactam), carbapenems (imipenem/meropenem), and fluoroquinolones (levofloxacin).
Statistical analysis
The Cochran Armitage Trend Test was used to identify statistically significant changes in susceptibility between 2004 and 2013. A positive change designated a statistically significant decrease in susceptibility; conversely, a negative change indicated that susceptibility had increased significantly. A statistical significance cut-off value of p < 0.01 was used in this analysis. Imipenem and meropenem data were excluded from the statistical analysis. As previously reported imipenem was replaced by meropenem in 2006 so data for the full period of study were not available for these two antimicrobials. Comparative 
Results

Enterobacteriaceae
The Enterobacteriaceae accounted for 118,899 isolates globally between 2004 and 2013. Susceptibility was highest to imipenem (97.1%), meropenem (97.0%), tigecycline (97.0%), and amikacin (96.9%) ( Table 1) . Globally, statistically significant decreases (p < 0.001-0.0001) in susceptibility were reported against the majority of antimicrobial agents and statistically significant (p < 0.01) changes in susceptibility were observed in all regions (Additional file 1: Table S1 ).
Among MDR Enterobacteriaceae (n = 9,372; Table 1 ), statistically significant changes in susceptibility were observed in all regions excluding the Middle East; most of these changes (20/28) represented decreases in susceptibility (Additional file 1: Table S1 ).
Enterobacter spp
A total of 32,987 isolates of Enterobacter spp. were collected between 2004 and 2013 (Table 2) . High (>95%) levels of susceptibility were observed for amikacin, imipenem, meropenem, and tigecycline. Among the 578 carbapenem-resistant (Car-R) isolates, the highest susceptibility rate was reported for tigecycline (83.0%).
Statistically significant decreases in global susceptibility were recorded to cefepime, ceftriaxone, minocycline, and piperacillin-tazobactam (each p < 0.0001) between 2004 and 2013 (Additional file 1: 
Klebsiella oxytoca
Globally, K. oxytoca (n = 6,940) were highly susceptible (>96%) to amikacin, cefepime, imipenem, meropenem, and tigecycline (Table 2 ). In Asia/Pacific Rim, statistically significant decreases in amikacin, minocycline (each p < 0.0001), and levofloxacin (p < 0.01) susceptibility were observed; globally, piperacillin-tazobactam susceptibility decreased significantly (p < 0.01) while tigecycline susceptibility increased significantly (p < 0.01) from 98.6% in 2004 to 99.4% in 2013 (Additional file 1: Table S1 ). Only 301 ESBL-producing K. oxytoca isolates were identified Table 2) . Statistically significant reductions in susceptibility among K. pneumoniae were noted to most antimicrobials globally as well as in Asia/Pacific Rim and Europe (Additional file 1: Table S1 ). Carbapenem-resistant K. pneumoniae demonstrated low (≤10.1%) and significantly decreased susceptibility to amoxicillin-clavulanate, cefepime, ceftriaxone, levofloxacin, and piperacillintazobactam globally (Additional file 1: Table S1 ).
ESBL production, observed in 5,899 (20.4%) K. pneumoniae isolates globally, was highest in Africa (42.8%, 249/ 582) and lowest in North America (9.5%, 983/10,366). Susceptibility among these isolates was highest to tigecycline (92.3%) and imipenem (91.3%) ( Table 2) Statistically significant decreases in antimicrobial susceptibility were reported globally among ESBLpositive K. pneumoniae for cefepime and minocycline (both p < 0.0001) as well as ceftriaxone (p < 0.001), while increases in susceptibility were recorded to amikacin (p < 0.0001) and piperacillin-tazobactam (p < 0.01) (Additional file 1: Table S1 ).
Serratia marcescens
Globally, a total of 13,006 S. marcescens isolates were collected. Susceptibility was high (>92%) to most agents on the panel with the exceptions of ampicillin (2.7%), amoxicillin-clavulanate (3.3%), minocycline (72.3%), and ceftriaxone (79.6%). Carbapenem resistance was observed in 229 (1.8%) isolates ( Table S1 ).
Acinetobacter baumannii
The highest levels of in vitro susceptibility against A. baumannii isolates (n = 16,778) in this study were reported for minocycline (84.5%) and imipenem (80.0%) ( Table 3) . No breakpoints are available for tigecycline, for which a MIC 90 of 2 mg/L was observed. More than 40% (6,743/16,778) of A. baumannii isolates were MDR globally (Table 3) , with rates highest in Africa (59.4%, 202/340), Middle East (67.2%, 452/673), and Latin America (67.8%, 1,388/2,048) (data not shown); the highest levels of susceptibility against these MDR isolates was observed for minocycline (70.3% susceptible), while tigecycline retained a MIC 90 of 2 mg/L (Table 3) .
Significant decreases in susceptibility were observed to all antimicrobials with available breakpoints globally (all p < 0.0001) (Additional file 1: Table S1 ). Among MDR A. baumannii, significant reductions in global susceptibility were noted to minocycline, and piperacillin-tazobactam (p < 0.0001). Significant increases in MDR A. baumannii susceptibility were observed to amikacin (p < 0.001) in Latin America, although susceptibility was only 8.8% during the complete study interval, and to minocycline (p < 0.001) in Africa.
Haemophilus influenzae
A total of 15,925 isolates of H. influenzae were collected globally. All isolates were highly susceptible (>98.5%) to the antimicrobial agents on the panel with the exception of ampicillin (78.3% susceptibility) (Table 3) .
Globally, increased ampicillin susceptibility was recorded (p < 0.001; 76 β-lactamase production was reported in 20.1% (3,207/ 15,925) of H. influenzae isolates globally; these isolates retained high susceptibility to most agents with the exception of ampicillin (0.2% susceptible; Table 3 ). No statistically significant changes in susceptibility were seen among β-lactamase-positive H. influenzae.
Pseudomonas aeruginosa
Globally, 28,413 P. aeruginosa isolates were collected between 2004 and 2013. These isolates showed a high Table S1 ). Susceptibility to several antimicrobial agents increased between 2011 and 2013: amikacin (by 6.7%), cefepime (7.6%), ceftazidime (13.5%), and piperacillin-tazobactam (13.7%).
Enterococcus faecalis
Global susceptibility among E. faecalis isolates (n = 14,615) was highest to linezolid (99.8%), tigecycline (99.7%), ampicillin (99.4%), and penicillin (99.2%) ( Table 4) .
Statistically significant reductions in ampicillin, minocycline, and penicillin susceptibility (each p < 0.0001) Enterococcus faecium, VR (n = 2,136)
were seen in Europe, North America, and globally; susceptibility to levofloxacin (p < 0.0001) and vancomycin (p < 0.01) increased globally (Additional file 2: Table S2 ). Minocycline susceptibility among E. faecalis decreased from 41.8% in 2004 to 26.6% in 2010 but subsequently increased to 36.7% in 2013.
Vancomycin resistance was observed among 325 isolates (2.2%) of E. faecalis globally; these resistant isolates were highly susceptible to linezolid, tigecycline, ampicillin, and penicillin (≥94.5%) ( Table 4) . Among vancomycin-resistant (VR) isolates, ampicillin, minocycline, and penicillin susceptibility decreased significantly lobally (p < 0.0001, p < 0.0001 and p < 0.001, respectively) and in North America (each p < 0.0001) (Additional file 2: Table S2 ).
Enterococcus faecium
In total, 6,167 isolates of E. faecium were submitted globally. Susceptibility was highest to tigecycline (99.7%) and linezolid (99.2%). Among all E. faecium, 2,136 (34.6%) isolates were vancomycin-resistant (Table 4) .
Tigecycline susceptibility in North America decreased significantly (p < 0.01), from 100% in 2004 to 97.9% in 2011 before returning to 100% in 2013; decreased A global decrease in minocycline susceptibility (p < 0.0001) was observed among VR E. faecium isolates. Tigecycline susceptibility among VR E. faecium decreased significantly (p < 0.01) in North America, although susceptibility through the 2004-2013 period was high (99.2%; Additional file 2: Table S2 ). Table S2 ).
Staphylococcus aureus
Discussion
Statistically significant changes in antimicrobial susceptibility have been reported among all organisms monitored in this study, with 410 such changes observed here; of these, 331 (81%) represented decreases in susceptibility. Globally, significant changes were observed in 106 cases, 85 of which (80%) denoted decreased susceptibility. Regionally, significant susceptibility changes were most common in Europe (71), Asia/Pacific Rim (67) and North America (68); decreases in susceptibility were reported in 54 (76%), 65 (97%), and 53 (78%) of cases, respectively. Widespread regional declines in antimicrobial susceptibility (or increases in resistance) have previously been shown, including Europe [11] , Asia [12] , and North America [13] . Statistically significant changes in susceptibility were observed most often among A. baumannii (32), E. coli (34), K. pneumoniae (30), and S. pneumoniae (31); among these, significant decreases in susceptibility were observed in 30 (94%), 33 (97%), 29 (97%) and 29 (94%) cases, respectively. These changes reflect other recent reports of declining susceptibility among important pathogens, including P. aeruginosa [13] , E. coli [14] , K. pneumoniae [15, 16] , and S. pneumoniae [17] .
A. baumannii susceptibility decreased in this report, both globally and regionally, to most antimicrobials; 47.1% of A. baumannii isolates from Asia/Pacific Rim were MDR. Molton et al. [12] reported similar results, with 55% of A. baumannii isolates from Singapore being MDR. A. baumannii are adept at acquiring resistance mechanisms and in expanding their global distribution [18] ; for example, meropenem susceptibility among A. baumannii from a tertiary care teaching hospital in Mexico decreased from 91.7% in 1999 to 11.8% in 2011 while imipenem susceptibility decreased from 88.2% to 13.9% [19] . These examples highlight the importance of monitoring highly resistant pathogens such as A. baumannii, which have the potential to become panresistant [12] .
The activity of tigecycline against resistant clinical bacteria collected globally in 2011 was described by Sader et al. [20] as a part of the SENTRY Antimicrobial Surveillance Program. Tigecycline susceptibility levels of 100% were reported among MRSA, 99.9% among ESBLpositive E. coli, 99.5% among vancomycin-resistant Enterococcus spp., 99.4% among PRSP, and 97.7% among ESBL-positive Klebsiella spp.; also, a tigecycline MIC 90 of 2 mg/L was reported by Sader et al. [20] for Acinetobacter. In a separate study, Sader et al. [21] reported good tigecycline activity against clinical isolates collected in the USA between 2006 and 2012, including MDR phenotypes, with no upwards trends in tigecycline resistance reported. These results accentuate the good in vitro activity of tigecycline against resistance phenotypes in the current study, including ESBL-positive and carbapenem-resistant E. coli, vancomycin-resistant enterococci, MRSA, and PRSP. Tigecycline was also active against carbapenem-resistant Enterobacter spp., with 95.4% of all isolates and 83.0% of carbapenem-resistant isolates susceptible to tigecycline; the next most active antimicrobial against carbapenem-resistant isolates was amikacin, with 68.3% of isolates susceptible. The good in vitro activity of tigecycline against resistant pathogens suggests it may have an important role in the treatment of infections caused by these difficult-to-treat pathogens.
Global susceptibility of Enterobacter spp., K. pneumoniae, S. marcescens, and S. pneumoniae to minocycline increased in this study by ≥20% between 2011 and 2012; this increase has not been reported in previously published studies. The numbers of centres participating in the TEST study increased globally from 197 in 2011 to 398 in 2012; this large influx of isolates from new centres in 2012 may be responsible for the observed susceptibility changes that year. This highlights one of the limitations of longitudinal surveillance studies: inconsistent centre involvement over time, with some centres contributing isolates in several years but others in only a single year. Another bias in TEST is the regional distribution of centres: Europe and the US account for more than two thirds of the centres participating in this study (72.9%, 443/608), thus global results reported are heavily influenced by trends in these regions. 
